Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 29300-155

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 29300-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 01

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 02

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 03

The text describes a graph or chart showing the mean change between a placebo (N=167) and Altuzosin hydrochloride extended-release tablets (N=170) at different treatment durations (28, 56, and 84 days). The graph also indicates a statistically significant difference (p<0.001) between the two treatments.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 04

This text appears to be a data table showing the mean change in some variable after a certain number of days of treatment with a placebo or Alfuzosin hydrochloride extended-release tablets. The number of participants in each group is also provided. The significance level of p < 0.01 is noted. However, the variable being measured and the units are not specified, so it is not possible to provide a more specific description.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 05

This appears to be a graph presenting the mean change in something over 28 and 56 days of treatment with a placebo compared to Altuzosin hydrochloride extended-release tablets, where the latter achieved a statistically significant improvement (p < 0.01) over the former. The specific thing being measured is not provided, so further information is not available.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 06

The text shows a graph displaying the mean change in mL/s for a placebo group and a group treated with alfuzosin hydrochloride extended-release tablets over 56-84 days. The graph indicates a statistically significant difference between the two groups.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 07

This appears to be a graph representing the mean change in mL/s over time for a placebo group and a group taking Alfuzosin hydrochloride extended-release tablets. The x-axis appears to represent days of treatment, while the y-axis represents mean change in mL/s. The graph shows that the group taking the medication saw a greater mean change in mL/s over time compared to the placebo group. The asterisk next to "p<0.05" suggests that this difference is statistically significant.*

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 08

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 09

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 10

FDA Label Image

Ef35abcf E0b6 4551 84cf A689ad11e6cd 11

This text provides information about a medication called "Extendodoieaso tablet" that contains "Oscemsarans e eB[fUZ0STN Hydrochloride". The drug comes in a container that is light-resistant and meets the USP standards. It is recommended to store the drug at 20-25°C. The drug is extended-release tablets and should be kept out of reach of children. The manufacturer of the drug is Unichem Laboratories Ltd. The text also provides information about the location of manufacturing of this drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.